 Connection
Masanori Hayashi to Prognosis
This is a "connection" page, showing publications Masanori Hayashi has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.238 |
|
|
|
-
Hayashi M, Chu D, Meyer CF, Llosa NJ, McCarty G, Morris CD, Levin AS, Wolinsky JP, Albert CM, Steppan DA, Park BH, Loeb DM. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer. 2016 10; 122(19):3015-23.
Score: 0.080
-
Hayashi M, Strouse JJ, Veltri MA, Curtis BR, Takemoto CM. Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children? Pediatr Blood Cancer. 2015 May; 62(5):922-3.
Score: 0.073
-
Weiser DA, Hayashi M, Applebaum MA. Breaking Up Isn't Hard to Do: Isolating Cell-free DNA Fragments in Osteosarcoma. Clin Cancer Res. 2023 06 01; 29(11):2017-2019.
Score: 0.032
-
Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 10; 59(10):1129-1139.
Score: 0.027
-
Oesterheld JE, Reed DR, Setty BA, Isakoff MS, Thompson P, Yin H, Hayashi M, Loeb DM, Smith T, Makanji R, Fridley BL, Wagner LM. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatr Blood Cancer. 2020 07; 67(7):e28370.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|